N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide Chemical Properties

Boiling point:

639.7±50.0 °C(Predicted)

Density 

1.486±0.06 g/cm3(Predicted)

storage temp. 

Sealed in dry,Room Temperature

pka

10.11±0.26(Predicted)

Appearance

Off-white to light brown Solid

InChI

InChI=1S/C17H15FN2O3/c18-11-1-3-12(4-2-11)19-15(22)17(9-10-17)16(23)20-13-5-7-14(21)8-6-13/h1-8,21H,9-10H2,(H,19,22)(H,20,23)

InChIKey

FSFMBVMXIPQPMJ-UHFFFAOYSA-N

SMILES

C1(C(NC2=CC=C(O)C=C2)=O)(C(NC2=CC=C(F)C=C2)=O)CC1

N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide Usage And Synthesis

Uses

N-(4-Fluorophenyl)-N''-(4-hydroxyphenyl)-1,1-cyclopropanedicarboxamide can be used to treat kinase-dependenet disorders.

Synthesis

GENERAL STEPS: To a solution of 4-aminophenol (2.93 g, 26.9 mmol) and 1-(4-fluorophenylcarbamoyl)cyclopropanecarboxylic acid (5.00 g, 22.4 mmol) in N,N-dimethylacetamide (DMA, 30 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 5.15 g, 26.9 mmol). The reaction mixture was stirred vigorously at room temperature until the reaction was complete (monitored by TLC, about 3 hours). Upon completion of the reaction, the reaction mixture was slowly poured into a flask containing saturated sodium bicarbonate (NaHCO3, 200 mL) aqueous solution under vigorous stirring. After continued stirring for 1 h, the resulting suspension was filtered. The solid product was collected, washed sequentially with water (50 mL) and chloroform (50 mL), and then dried under vacuum to afford N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide (6.22 g, 88% yield) as a white powder (HPLC purity >95%, and structure confirmed by 1H NMR).

References

[1] Patent: WO2005/30140, 2005, A2. Location in patent: Page/Page column 205
[2] Patent: CN106632028, 2017, A. Location in patent: Paragraph 0079; 0084; 0085
[3] Patent: WO2005/30140, 2005, A2. Location in patent: Page/Page column 205
[4] European Journal of Medicinal Chemistry, 2017, vol. 140, p. 212 - 228

N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide(849217-60-3)Related Product Information

• 4-Aminoveratrole
• Cabozantinib Impurity 5
• 4-chloro-6,7-dimethoxyquinoline
• Cabozantinib Impurity EXA
• Cabozantinib impurity DX2
• 1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid
• Cyclopropanecarboxylic acid, 1-[[[4-[[7-methoxy-6-(sulfooxy)-4-quinolinyl]oxy]phenyl]amino]carbonyl]-
• 1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-phenyl-
• Quinoline, 6,7-dimethoxy-4-(4-nitrophenoxy)-
• Cyclopropanecarboxylic acid, 1-[(phenylaMino)carbonyl]-
• Cabozantinib Malate
• 1,1-Cyclopropanedicarboxamide, N,N'-bis[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-
• Cabozantinib impurity 1DYH
• Cyclopropanecarboxylic acid, 1-[[(2-fluorophenyl)amino]carbonyl]-